Consequently, peptides [74] and antibodies [75] that specifically target S100A9 in the colon have shown efficacy in mouse models, reducing both colitis and CAC by inhibiting their interactions with TLR4 and RAGE. The gene discussed is S100A9; the disease is colitis.